NCT00935012 - Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 20, 2019

Study Completion Date

November 20, 2019

Conditions

ATTR-CMTTR-CM

Interventions

DRUG

tafamidis

Once daily 20 mg oral tafamidis (soft gelatin capsule)

Trial Locations (7)

Johns Hopkins Hospital, Baltimore

The University of Chicago Medical Center, Chicago

University of Chicago Medical Center, Chicago

University of Chicago, Chicago

Emory University School of Medicine, Atlanta

Brigham and Women's Hospital, Boston

Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), New York